Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PHPharvaris N.V. logo

Pharvaris N.V. (PHVS)

NASDAQ · Currency in USD
$31.41 ▲ +0.73 (+2.38%)
At close: Oct 23, 4:00 PM ET. Market closed.
$31.25 ▼ -0.16 (-0.51%)
Pre-market: Oct 26, 4:00 AM ET

Summary

Previous Close
$30.68
Open
$31.57
Day's Range
$30.25 – $32.12
52 Week Range
$21.02 – $43.25
Volume
621,710
Avg. Volume
699,443
Market Cap
$2.19B
Beta (5Y Monthly)
-2.46
PE Ratio (TTM)
--
EPS (TTM)
-$2.52
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$60.73

Profile: Pharvaris N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
148
CEO
Berndt Modig

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.82 · Revenue est. $2.35M
DateEst.Actual
Aug 12, 2026-$0.75-$0.81Miss
May 12, 2026-$0.82-$0.70Beat
Apr 2, 2026-$0.71-$0.85Miss
Nov 12, 2025-$0.78-$0.70Beat
Aug 12, 2025-$0.87-$0.94Miss
May 13, 2025-$0.80-$0.89Miss

Analyst view

Consensus price target
$60.73 ▲ +93.3%
Range $44.00 – $75.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PHVS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.